SINGAPORE – 9 Aug 2024 – Tikva Allocell (Tikva), founded July 2023 celebrated our first year anniversary. Headquartered in Singapore, the company’s mission is to develop safe, efficacious, and cost-effective “off-the-shelf” T cell therapies. Our focus lies in leveraging the allogeneic Epstein-Barr Virus-Specific T (EBVST) cells platform to treat cancers.
Within this past year, we have built an awesome team, and have set up strategic partnerships with academic institutions in the US and Singapore. In addition, our scientists have published three peer-reviewed papers and presented at numerous scientific meetings. Tikva’s accomplishments are, in no small part, contributed by its dedicated scientists and professionals. We will continue to strive for excellence as we advance our pipeline to inspire hope for cancer patients!
Jinkai TEO, MSc
Principal Data Scientist
Jinkai brings more than 10 years of experience in the pharmaceutical industry spanning from the bench as a translational scientist at Merck Sharp & Dohme (MSD) and managing analytics on CMC related activities (analytical development, DoE and QoD) at Tessa Therapeutics.